Vaccine Programs

Infectious Disease

Preclinical
Phase 1
Phase 2
Phase 3
Approved

HBV

Hepatitis B
Licensed in 15 Countries

Approved (Sci-B-Vac®)

100%

HBV

Hepatitis B
US, EU, CAN

Phase 3 (Sci-B-Vac®)

68%

CMV

Cytomegalovirus

Phase 1 (VBI-1501)

35%

Zika virus

Preclinical

6%

Immuno-Oncology

Preclinical
Phase 1
Phase 2
Phase 3
Approved

GBM

Glioblastoma multiforme

Phase 1/2a (VBI-1901)

30%

MB

Medulloblastoma

Preclinical (VBI-1901)

15%